296 filings
8-K
OGEN
Oragenics Inc
7 May 24
Oragenics Partners with Avance Clinical for Phase II Concussion Trial in Australia
8:14am
8-K
OGEN
Oragenics Inc
19 Apr 24
Oragenics, Inc. Announces Notification of Noncompliance with Additional NYSE American Continued Listing Standards
5:48pm
8-K
OGEN
Oragenics Inc
15 Apr 24
Shareholder Nominations Pursuant to Exchange Act Rule 14a-11
8:01pm
8-K
OGEN
Oragenics Inc
18 Mar 24
Oragenics Appoints James Kelly MD, Chief Medical Officer to Lead Phase II Clinical Trials for Treating Concussion
7:38am
8-K
OGEN
Oragenics Inc
1 Mar 24
Oragenics Announces Closing of Public Offering
4:05pm
8-K
8ig9qkdws fmj0
28 Feb 24
Oragenics Announces Pricing of Public Offering
9:03am
8-K
99gss
27 Feb 24
Oragenics Announces Proposed Public Offering
5:48pm
8-K
9zv2d g9y2sucw
12 Feb 24
Oragenics, Inc. Announces Leadership Transition
4:45pm
8-K
lcw92qej7khxy3nxss0j
7 Feb 24
Oragenics, Inc. Announces Expiration of Its Investment Banking Engagement Agreement
8:00am
8-K
ltlqg94obxppz zfqi3
5 Feb 24
Other Events
8:00am
8-K
8rcmd9g
23 Jan 24
Oragenics Announces Termination of At-The-Market Offering Program
5:18pm
8-K
qjxf7n5u9y
16 Jan 24
Other Events
9:10am
8-K
imhu5r1 oh6prd
2 Jan 24
Oragenics Completes Acquisition of Odyssey Health’s Neurological Assets
9:22am
8-K
csu3ije
29 Dec 23
Completion of Acquisition or Disposition of Assets
7:30am
8-K
xohm eqbdlm5ntt
15 Dec 23
Material Modifications to Rights of Security Holders
3:45pm
8-K
gvum631nobo24p
8 Dec 23
Amendments to Articles of Incorporation or Bylaws
4:00pm
8-K
stuj9q24ey
20 Nov 23
Regulation FD Disclosure
3:45pm
8-K
7jc47hm1ad z1
2 Nov 23
Oragenics Issues Update to Shareholders
7:00am
8-K
9f042
5 Oct 23
Departure of Directors or Certain Officers
5:29pm
8-K
kpb0owk92lu9ynzjjfdy
5 Oct 23
Oragenics to Acquire Odyssey Health’s Neurological Drug Technology Pipeline Including Concussion Drug Candidate
6:30am